Muribaculaceae can be increased using the sodium-glucose cotransporter 2 inhibitors canagliflozin and dapagliflozin to prevent DN progression as well as the onset of end-stage renal disease independent of lowering glucose levels (Wu et al., 2023). Here, SLC5A2 is linked to chronic kidney disease.